IL315655A - Pharmaceutical compositions of human recombinant acid sphingomyelinase and methods - Google Patents

Pharmaceutical compositions of human recombinant acid sphingomyelinase and methods

Info

Publication number
IL315655A
IL315655A IL315655A IL31565524A IL315655A IL 315655 A IL315655 A IL 315655A IL 315655 A IL315655 A IL 315655A IL 31565524 A IL31565524 A IL 31565524A IL 315655 A IL315655 A IL 315655A
Authority
IL
Israel
Prior art keywords
compositions
methods
recombinant human
human acid
acid sphingomyelinase
Prior art date
Application number
IL315655A
Other languages
English (en)
Hebrew (he)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL315655A publication Critical patent/IL315655A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/203—Equilibration or regeneration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL315655A 2022-03-18 2023-03-17 Pharmaceutical compositions of human recombinant acid sphingomyelinase and methods IL315655A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263321636P 2022-03-18 2022-03-18
PCT/US2023/064657 WO2023178325A1 (en) 2022-03-18 2023-03-17 Pharmaceutical recombinant human acid sphingomyelinase compositions and methods

Publications (1)

Publication Number Publication Date
IL315655A true IL315655A (en) 2024-11-01

Family

ID=86051983

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315655A IL315655A (en) 2022-03-18 2023-03-17 Pharmaceutical compositions of human recombinant acid sphingomyelinase and methods

Country Status (12)

Country Link
US (1) US20230365946A1 (https=)
EP (1) EP4493684A1 (https=)
JP (1) JP2025509722A (https=)
KR (1) KR20240156645A (https=)
CN (1) CN119365593A (https=)
AR (1) AR128825A1 (https=)
AU (1) AU2023235321A1 (https=)
CA (1) CA3254814A1 (https=)
IL (1) IL315655A (https=)
MX (1) MX2024011382A (https=)
TW (1) TW202403043A (https=)
WO (1) WO2023178325A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4594462A1 (en) 2022-09-28 2025-08-06 Genzyme Corporation Systems and devices for producing biological products and methods of using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US20020137173A1 (en) * 2001-02-05 2002-09-26 Dae-Kyong Kim Membrane-associated sphingomyelinase derived from bovine brain, isolation method therefor and anti-sphingomyelinase monoclonal anitibody
US7527956B2 (en) * 2003-06-12 2009-05-05 Genzyme Corporation Modified human acid sphingomyelinase having increased activity, and methods for making the same
WO2008085988A1 (en) 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
KR20100103595A (ko) 2008-01-18 2010-09-27 에프. 호프만-라 로슈 아게 비-글라이코실화된 단백질의 정제
RU2012151132A (ru) 2010-05-19 2014-06-27 Ф. Хоффманн-Ля Рош Аг Хроматография с гиброфобным взаимодействием
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
EP2997036B1 (en) 2013-05-15 2021-03-03 Medimmune Limited Purification of recombinantly produced polypeptides
DK3728287T3 (da) 2017-12-19 2024-06-10 CSL Behring Lengnau AG Proteinoprensning og virusinaktivering med alkylglycosider
PY1939780A (es) 2018-05-25 2019-12-04 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida

Also Published As

Publication number Publication date
JP2025509722A (ja) 2025-04-11
TW202403043A (zh) 2024-01-16
WO2023178325A1 (en) 2023-09-21
KR20240156645A (ko) 2024-10-30
US20230365946A1 (en) 2023-11-16
AR128825A1 (es) 2024-06-19
CA3254814A1 (en) 2023-09-21
AU2023235321A1 (en) 2024-10-31
MX2024011382A (es) 2024-09-23
CN119365593A (zh) 2025-01-24
EP4493684A1 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
GB2611642B (en) Pharmaceutical and cosmetic compositions comprising secretomes
IL320856A (en) Pharmaceutical combinations and their uses
IL316170A (en) Pharmaceutical compositions of therapeutic proteins and methods of use
EP4114430A4 (en) TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS
IL315655A (en) Pharmaceutical compositions of human recombinant acid sphingomyelinase and methods
LT3981390T (lt) Lakozamido farmacinė kompozicija ir jos farmacinis preparatas
PT3958889T (pt) Composições de péptidos miméticos de colagénio para o tratamento de uma doença ou perturbação ocular so segmento posterior que envolve a retina, os vasos sanguíneos da retina, os nervos retinianos ou o nervo ótico
EP4291225A4 (en) RECOMBINANT HUMAN ACID ALPHA-GLUCOSIDASE AND USES THEREOF
HK40120786A (en) Pharmaceutical recombinant human acid sphingomyelinase compositions and methods
SG11202102400PA (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
IL286416A (en) Pharmaceutical formulations of abiraterone-ring oligomer and methods for their preparation and administration
MX2025002733A (es) Composiciones farmaceuticas para el tratamiento de la deficiencia de esfingomielinasa acida
IL285362A (en) Oral formulations of biologically active peptide and uses thereof
IL319382A (en) Pharmaceutical preparation and its use
IL318702A (en) Compositions containing G-CSF and their uses
ES3064824T3 (en) Pharmaceutical formulations of bictegravir and lenacapavir
GB202408903D0 (en) Pharmaceutical compositions and medical uses
HK40105005A (en) Recombinant human acid alpha-glucosidase and uses thereof
HUP2200147A1 (hu) Palbociclibet és letrozolt tartalmazó gyógyszerkészítmény
IL319282A (en) Artificial protein and pharmaceutical composition
GB202219597D0 (en) Formulations and methods for delivering dietry and pharmaceutical ingredients
GB202119021D0 (en) Injectable and inhalable formulations
GB202507879D0 (en) Pharmaceutical composition and uses
GB202300911D0 (en) Therapeutic compositions and methods
CA3304242A1 (en) Pharmaceutical formulations comprising 5-meo-dmt and their therapeutic uses